Status:
COMPLETED
Treatment of Tardive Dyskinesia With Galantamine
Lead Sponsor:
Caroff, Stanley N., M.D.
Collaborating Sponsors:
Ortho-McNeil Neurologics, Inc.
Conditions:
Tardive Dyskinesia
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Tardive dyskinesia (TD), a form of movement disorder, remains a problem for some patients who received antipsychotic medications. Increasing evidence suggests that TD may result from antipsychotic-ind...
Detailed Description
BACKGROUND: Tardive dyskinesia (TD) is an infrequent but important complication of treatment with antipsychotic medications. Although newer antipsychotics may be less likely to cause TD, it still occu...
Eligibility Criteria
Inclusion
- Clinical diagnosis of tardive dyskinesia lasting at least 3 months
- Treatment with antipsychotic drugs at least for 3 months
- 18 years old or older
Exclusion
- Significant active medical illness
- Allergy to galantamine
- Pregnancy
- Drug or alcohol dependence
- Necessary use of anticholinergics or vitamin E
Key Trial Info
Start Date :
January 1 2002
Trial Type :
INTERVENTIONAL
End Date :
October 1 2004
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00164242
Start Date
January 1 2002
End Date
October 1 2004
Last Update
September 14 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Philadelphia VA Medical Center
Philadelphia, Pennsylvania, United States, 19104